NAMA: A Drug Target / Disease Biomarker (G100996569)

Target Name: NAMA

NCBI ID: G100996569

NAMA

Other Name(s): NAMA variant 1 | Non-protein coding RNA, associated with MAP kinase pathway and growth arrest, transcript variant 1 | non-protein coding RNA, associated with MAP kinase pathway and growth arrest

NAMA: A Drug Target / Disease Biomarker

NAMA is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the superfamily of nucleotide-binding proteins (NBP), which are a type of transmembrane protein that can interact with nucleotides such as DNA and RNA.

One of the unique features of NAMA is its ability to interact with and modulate the activity of several different nucleotides. This makes it an attractive target for drug development, as it allows for the development of compounds that can specifically modulate the activity of NAMA and improve its function.

NAMA has been shown to play a role in several physiological processes in the body, including cell signaling, DNA replication, and metabolism. It has also been implicated in a number of diseases, including neurodegenerative diseases and cardiovascular disease.

One of the key challenges in studying NAMA is its complex structure and the difficulty of studying its function in living organisms. Despite these challenges, research into NAMA has led to several important findings about its role in the body and its potential as a drug target.

One of the key findings about NAMA is its involvement in the regulation of DNA replication. NAMA has been shown to interact with the proteinINK4a, which is involved in the replication of DNA in the cell. This interaction between NAMA and INK4a suggests that NAMA may play a role in regulating the production of new DNA copies in the cell, which could be important for the development and progression of cancer.

Another important finding about NAMA is its role in neurodegenerative diseases. NAMA has been implicated in the development and progression of a number of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that NAMA may be a useful target for the development of new treatments for these conditions.

In addition to its involvement in neurodegenerative diseases, NAMA has also been shown to be involved in the regulation of metabolism. NAMA has been shown to interact with the proteinSIRT6, which is involved in the metabolism of lipids and other nutrients in the cell. This interaction between NAMA and SIRT6 suggests that NAMA may play a role in regulating the metabolism of the cell, which could be important for a wide range of diseases.

Despite these promising findings, the development of NAMA-based drugs has been slow. One of the main challenges is the difficulty of studying NAMA in live organisms, as the protein is difficult to purify and manipulate in this way. In addition, the structure of NAMA is complex and its function is not well understood. This makes it difficult to design small molecules that can specifically modulate its activity.

Despite these challenges, researchers are continuing to study NAMA and its potential as a drug target. The hope is that these studies will lead to the development of new treatments for a wide range of diseases.

Protein Name: Non-protein Coding RNA, Associated With MAP Kinase Pathway And Growth Arrest

The "NAMA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAMA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets